Get started
Author

Tomohiko Nakatogawa

ORCID: 0009-0007-2836-4649
Observed ORCID: 0009-0007-2836-4649
OpenAlex ID: A5020434787
Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
2024 · Yoshitaka Honma, Nobuya Monden, et al. · Clinical Cancer Research · 20
PDF
Data from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
2024 · Yoshitaka Honma, Nobuya Monden, et al. · 1
Data from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
2024 · Yoshitaka Honma, Nobuya Monden, et al. · 1
Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (pts) with far locally advanced or recurrent/metastatic (fLA/RM) and androgen receptor (AR)-expressing salivary gland carcinoma (SGC).
2022 · Yoshitaka Honma, Nobuya Monden, et al. · Journal of Clinical Oncology · 1
Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma
2026 · Kenshi Suzuki, Hiroshi Kosugi, et al. · Japanese Journal of Clinical Oncology
Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial
2026 · Kenshi Suzuki, Morio Matsumoto, et al. · International Journal of Hematology
PDF
Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
2024 · Yoshitaka Honma, Nobuya Monden, et al.
Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
2024 · Yoshitaka Honma, Nobuya Monden, et al.
Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
2024 · Yoshitaka Honma, Nobuya Monden, et al.
Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
2024 · Yoshitaka Honma, Nobuya Monden, et al.
Works count: 10
Citation count: 23
H-index: 1
I10-index: 1
Year
Topic
Type